drugset
Drugs / TOL2506
last change Dec 2022 re-read 9 days ago

TOL2506

also known as Leuprolide Acetate
Developed for
breast cancer · female breast carcinoma
Investigated by
Tolmar Inc.

Trials 2

today NCT05645536 · Ph 3 NCT04906395 · Ph 3
202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05645536 Dec 2022 → Mar 2030 expected breast cancer Tolmar Inc. Enrolling by invitation No outcome recorded
Phase 3 NCT04906395 Jul 2021 → Nov 2026 expected female breast carcinoma Tolmar Inc. Active not recruiting No outcome recorded

Press releases naming this drug 6 releases

DateIssuerRelease
2019-08-02 Tolmar Inc. Data on Nadir Testosterone Levels Achieved by ELIGARD® (leuprolide acetate) for injectable suspension published in Reviews in Urology tolmar.com ↗
2017-05-14 Tolmar Inc. Data From Tolmar Pharmaceuticals on ELIGARD Demonstrate Serum Leuprolide Levels Required to Maintain Stable, Long-Term Testosterone Suppression Across All Doses Serum Level of Leuprolide Acetate Required to Maintain Low T Established tolmar.com ↗
2017-05-08 Tolmar Inc. Tolmar, Inventor and Developer of ELIGARD® (leuprolide acetate for injectable suspension), Announces Plans to Expand Manufacturing Facilities in Colorado tolmar.com ↗
2016-05-06 Tolmar Inc. Tolmar Pharmaceuticals Announces That FDA Approval Has Been Received For ELIGARD® (leuprolide acetate for injectable suspension) Storage at Room Temperature For up to 8 Weeks tolmar.com ↗
2015-05-18 Tolmar Inc. Data From Tolmar Pharmaceuticals Demonstrate ELIGARD® (leuprolide acetate for injectable suspension) Consistently Suppresses Serum Testosterone Levels in Patients With Advanced Prostate Cancer tolmar.com ↗
2014-05-16 Tolmar Inc. Tolmar Pharmaceuticals Established to Market ELIGARD® (leuprolide acetate for injectable suspension) For Advanced Prostate Cancer in the U.S. and Puerto Rico tolmar.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as TOL2506 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05645536 ↗
1

NCT04906395 ↗
Known as Leuprolide Acetate “Leuprolide Acetate for injectable suspension, 30 mg. Subcutaneous injection every 3 months.” NCT04906395 ↗
Route Subcutaneous “Subcutaneous injection every 3 months.” NCT04906395 ↗